Introduction
Secondary amyloidosis is caused mainly by chronic inflammatory diseases such as rheumatoid arthritis and tuberculosis. Systemic amyloidosis with Castleman's disease was first reported by Plavnick et al in 1980 (1) and since then only eight cases (1-7) have been reported. However in only two cases amyloidosis was confirmed to be secondary (2, 3) . Here, we report the clinical course of a patient with systemic and secondary amyloidosis associated with intraabdominal Castleman's disease of the plasma cell type. Although surgical removal of the lymphomaimproved her clinical manifestations and laboratory findings, it did not halt the progression of renal insufficiency.
Case Report
A 53-year-old Japanese woman had suffered from bilateral leg edema since 1984. In 1988, she was found to have hypothyroidism and since then had been administered thyroxine. In 1990 her leg edema progressed and she was admitted to our hospital in August 1990. A physical examination on admission revealed hypertension (174/94 mmHg), low grade fever (37.4°C), diffusely hard struma and bilateral leg edema. No mass was palpated in the abdomen. Laboratory findings (Table 1) showed proteinuria, anemia, elevation of the erythrocyte sedimentation rate (ESR), hypoalbuminemia (2. 1 g/dl), polyclonal gammopathy and renal insufficiency (blood uremic nitrogen; BUN26 mg/dl, creatinine; Cr 1.9 mg/dl). Serological examination showed elevation of serum C-reactive protein (CRP). Creatinine clearance was severely reduced. Markedamyloid deposits were observed on renal biopsy. The biopsy of gastric mucosa also revealed amyloid deposits. The specimen from gastric mucosa was stained positively by antibody against SAA(serum amyloid protein A) (Fig. 1) . She was diagnosed to have systemic and secondary amyloidosis. On echocardiogram, diffuse thickening of the left ventricular wall (IVS thickness 1 3mm)with a "granular sparkling pattern" was found and its movementwas decreased, suggesting cardiac amyloidosis. Hypothyroidism could be due to amyloid deposition since the patient had no thyroid autoantibodies and no particular findings on echo or CT. On abdominal CT, a clearly bordered low density mass was found adjacent to the body of pancreas (Fig. 2) . Duodenographyrevealed that the mass compressed the fourth portion of the duodenum (Fig. 3) . On abdominal exploration, the mass was found in the left upper peritoneal space near Treitz' ligament. It had a stalk extending from the retroperitoneal space and was 5x5x5 cm in diameter, circumscribed and capsulated (Fig. 4) . The mass was removed and microscopic examination demonstrated numerous lymphoid follicles with various sized germinal centers.
Between the lymphoid follicles, were many plasma cells without pleomorphism (Fig. 5A, B) . These findings were compatible with Castleman's disease of the plasma cell type. After resection of the mass, low grade fever, elevation of ESR, hypoalbuminemia, elevation of serum CRPand polyclonal gammopathywere all improved and proteinuria was reduced. But renal insufficiency progressed and 20 months after the operation hemodialysis was begun (Fig. 6 ).
Discussion
In this case, secondary amyloidosis was diagnosed by positive staining with antibody against SAA. Secondary amyloidosis in this case was assumed to be caused by Castleman's disease, because no other cause for secondary amyloidosis could be found and removal of the lymphomaimproved various manifestations and inflammatory laboratory findings.
Castleman's disease was first described by Castleman et al in 1956 (8) and it is considered to be a hamartoma orhyperplasia globulinemia. It has been considered an immunological reaction to the disease. In previously reported cases of systemic amyloidosis with Castleman's disease, they were mostly PC type (1-7). In 1980 Plavnick et al reported systemic amyloidosis with an immunoblastic lymphadenopathy, but it was not defined whether the amyloid was AAtype or not (1) . In 1982 Bonneau et al reported a case of angiofollicular lymph node hyperplasia (PC type) accompanied with renal amyloidosis, in which the amyloid was defined as AA type (2). SAA, the precursor of the AAtype of amyloid, is one of the acute phase proteins in inflammation and its production is enhanced by interleukin-6 (IL-6) in hepatocytes (9, 10). It was revealed that large amounts of IL-6 are produced in the germinal centers of Castleman's disease (1 1). Therefore secondary amyloidosis in Castleman's disease can be caused by overproduction of SAAdue to IL-6 from the lymphoma. In the present case, we did not measure serum SAAlevel, but it was assumed to fall after the removal of the lymphoma because it usually is correlated with the serum C-reactive protein level (12). s-Cr: serum creatinine, HDinduction: hemodialysis induction, U-TP: urine total protein, CRP: C-reactive protein. associated with Castleman's disease have been reported (Table  2) . Most of these cases had nephrotic syndrome due to renal amyloidosis.
Three of the six cases showed improvement in renal insufficiency and/or other manifestations by treatment of the lymphoma (2, 4, 6) . One died of another disease (1) , and in the others their outcomes were not described in detail (3, 5) . Bonneau et al first reported a case in which proteinuria and various hematologic disturbances were improved after treatment of the lymphoma(2). Chan et al reported a case in which chemotherapy was effective in improving renal insufficiency and hemodialysis was not necessary (6). In the present case, however, removal of the lymphomadid not improve the renal insufficiency. It is possible that severe amyloid deposition in the kidneys in secondary amyloidosis may not be fully reversed by treatment of causative diseases.
